This special emphasis panel reviews small business applications in the general area of biomaterials, nanotechnology, and gene, protein and drug delivery technologies.
The List of Reviewers lists all present, whether standing members or temporary, to provide the full scope of expertise present on that date. Lists are posted 30 days before the meeting and are tentative, pending any last minute changes.
- Interdisciplinary bioengineering approaches for therapy and drug delivery
- Drug delivery including proteins, nucleic acids, viruses, liposomes, polymers, micelles, vesicles, nanoparticles, biomaterials, and cells
- Drug delivery vehicle formulation, manufacturing, biocompatibility, toxicity, and in vivo investigations
- Multifunctional nanoparticles in cellular imaging, sensing, targeted drug/gene delivery and theranostics
- Nanoparticle platforms for controlled release of proteins, nucleic acids, small molecules, and cells
- Tissue engineering, tissue scaffolds, biomaterials to support biocompatible/biodurable implants/sensors, ex vivo modeling, mechanobiology, physiological testing of chemotaxis/mechanotaxis, vascularization
- Organ-on-a-chip, D culture devices, chip- and micro-array-based microtechnologies and biosensors focused on biorecognition, biocompatibility, nonfouling surfaces, and biological fouling mechanisms
- Biomaterials, matrices, and polymeric scaffolds supporting the use of stem cells for tissue engineering, tissue regeneration, and wound healing
Shared Interests and Overlaps
There are shared interests with Cell and Molecular Biology (IMST (15)). Applications developing new cell-based technologies and assays may be assigned to IMST (15). Applications integrating cells into biomaterial constructs and/or studying the integration of biomaterials into cellular environments may be assigned to BST (10). Tissue engineering and microphysiological systems (e.g. organ-on-a-chip) applications are the domain of BST (10).